Lv1
2 积分 2024-07-05 加入
The oncogenic EGFR-SHC1 fusion confers insensitivity to EGFR-TKI via dual activation of N-EGFR kinase domain and C-SHC1 phosphorylation sites in lung cancer
8小时前
求助中
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial
22天前
已完结
Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment
1个月前
已完结
An Overlooked Cause of Severe Gastritis
1个月前
已完结
Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer
1个月前
已完结
Advances in Immunotherapy and Chemoradiotherapy Combination for Limited-Stage Small-Cell Lung Cancer: Current Landscape and Future Frontiers
1个月前
已完结
Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited-stage small-cell lung cancer: A retrospective, multi-center, real-world study
1个月前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
1个月前
已完结
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs
3个月前
已完结
Discovery of a brain-penetrant fourth-generation EGFR inhibitor to overcome the human triple (L858R/T790 M/C797S) mutation
3个月前
已完结
皖公网安备34019202002308
